LeMaitre Vascular

LMAT

Market cap $2.62B

BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.

2,625 shares were exercised and sold on March 11, 2026, generating a transaction value of approximately $285,000 at a weighted average sale price of around $108.50 per share. This disposition represented 28.22% of Kamke's direct holdings prior to the transaction, reducing direct ownership to 6,677 shares.

An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026. The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.

The market has been going through a visible rotation. Dividend payers have been outperforming so far this year as investors rotate from large-cap AI names into “old economy” stocks. If you own software names that depend on pricing power through expensive licensing, you need to revisit your thesis. Higher energy prices would ultimately filter through to consumer and producer prices, leaving central banks scrambling to reassess their interest rate trajectory.

After reaching an important support level, LeMaitre Vascular, Inc. (LMAT) could be a good stock pick from a technical perspective. LMAT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling guidance and a projected $10M in 2026. This could drive earnings growth for years to come. LMAT maintains a robust $190M net cash position and recently increased its dividend by 25%. The board has also authorized a $100M share repurchase program.

BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.

LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript

BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance.